Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
Dimitri Poddighe,1,2 Elena Kovzel2 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan; 2Clinical Academic Department of Pediatrics, University Medical Center (UMC), Nur-Sultan, 010000, KazakhstanCorrespondence: Dimitri Poddighe Email dimitri.poddighe@nu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-12-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/impact-of-anti-type-2-inflammation-biologic-therapy-on-covid-19-clinic-peer-reviewed-fulltext-article-JIR |
| _version_ | 1819179776174194688 |
|---|---|
| author | Poddighe D Kovzel E |
| author_facet | Poddighe D Kovzel E |
| author_sort | Poddighe D |
| collection | DOAJ |
| description | Dimitri Poddighe,1,2 Elena Kovzel2 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan; 2Clinical Academic Department of Pediatrics, University Medical Center (UMC), Nur-Sultan, 010000, KazakhstanCorrespondence: Dimitri Poddighe Email dimitri.poddighe@nu.edu.kzAbstract: SARS-CoV-2 pandemic had a general and deep impact on the clinical management of chronic diseases, including respiratory and allergic disorders. At the beginning of the pandemic, one of the main concerns was the potential impact of immunosuppressive/immunomodulatory drugs on COVID-19 clinical course. In this review, we aim to summarize and analyze the available clinical evidence from patients treated with anti-type 2 inflammation biologics (including anti-IgE, anti-IL-5 and anti-IL-4 agents), who developed COVID-19. Overall, the treatment with anti-Th2 biologics can be considered safe during COVID-19. It does not worsen the clinical course and outcome of COVID-19, and it may be actually protective somehow from developing severe forms. Moreover, patients treated with these biological agents do not seem to be more prone to get infected by SARS-CoV-2.Keywords: COVID-19, SARS-CoV-2, omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, asthma, chronic spontaneous urticaria, biologics |
| first_indexed | 2024-12-22T22:03:49Z |
| format | Article |
| id | doaj.art-8b55da835694421ea0d84d59ae88c7b6 |
| institution | Directory Open Access Journal |
| issn | 1178-7031 |
| language | English |
| last_indexed | 2024-12-22T22:03:49Z |
| publishDate | 2021-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj.art-8b55da835694421ea0d84d59ae88c7b62022-12-21T18:11:03ZengDove Medical PressJournal of Inflammation Research1178-70312021-12-01Volume 146845685371432Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and OutcomePoddighe DKovzel EDimitri Poddighe,1,2 Elena Kovzel2 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan; 2Clinical Academic Department of Pediatrics, University Medical Center (UMC), Nur-Sultan, 010000, KazakhstanCorrespondence: Dimitri Poddighe Email dimitri.poddighe@nu.edu.kzAbstract: SARS-CoV-2 pandemic had a general and deep impact on the clinical management of chronic diseases, including respiratory and allergic disorders. At the beginning of the pandemic, one of the main concerns was the potential impact of immunosuppressive/immunomodulatory drugs on COVID-19 clinical course. In this review, we aim to summarize and analyze the available clinical evidence from patients treated with anti-type 2 inflammation biologics (including anti-IgE, anti-IL-5 and anti-IL-4 agents), who developed COVID-19. Overall, the treatment with anti-Th2 biologics can be considered safe during COVID-19. It does not worsen the clinical course and outcome of COVID-19, and it may be actually protective somehow from developing severe forms. Moreover, patients treated with these biological agents do not seem to be more prone to get infected by SARS-CoV-2.Keywords: COVID-19, SARS-CoV-2, omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, asthma, chronic spontaneous urticaria, biologicshttps://www.dovepress.com/impact-of-anti-type-2-inflammation-biologic-therapy-on-covid-19-clinic-peer-reviewed-fulltext-article-JIRcovid-19sars-cov-2omalizumabdupilumabbenralizumabmepolizumabreslizumabasthmachronic spontaneous urticariabiologics |
| spellingShingle | Poddighe D Kovzel E Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome Journal of Inflammation Research covid-19 sars-cov-2 omalizumab dupilumab benralizumab mepolizumab reslizumab asthma chronic spontaneous urticaria biologics |
| title | Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome |
| title_full | Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome |
| title_fullStr | Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome |
| title_full_unstemmed | Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome |
| title_short | Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome |
| title_sort | impact of anti type 2 inflammation biologic therapy on covid 19 clinical course and outcome |
| topic | covid-19 sars-cov-2 omalizumab dupilumab benralizumab mepolizumab reslizumab asthma chronic spontaneous urticaria biologics |
| url | https://www.dovepress.com/impact-of-anti-type-2-inflammation-biologic-therapy-on-covid-19-clinic-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT poddighed impactofantitype2inflammationbiologictherapyoncovid19clinicalcourseandoutcome AT kovzele impactofantitype2inflammationbiologictherapyoncovid19clinicalcourseandoutcome |